Owning 30% shares,institutional owners seem interested in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
52% of the business is held by the top 7 shareholders 20% of ARS Pharmaceuticals is held by insiders Every investor in ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY ) should be aware of the most powerful shareholder groups. With 30% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. In the chart below, we zoom in on the different ownership groups of ARS Pharmaceuticals. Check out our latest analysis for ARS Pharmaceuticals What Does The Institutional Ownership Tell Us About ARS Pharmaceuticals? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do co
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- The Schall Law Firm Initiates Probe Into Claims Against ARS Pharmaceuticals Inc And Urges Affected Investors To ParticipateAccesswire
- ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)GlobeNewswire
- The Schall Law Firm Begins Investigation Into Allegations Against ARS Pharmaceuticals Inc And Encourages Impacted Investors To Get InvolvedAccesswire
- The Schall Law Firm Begins Investigation Into Allegations Against ARS Pharmaceuticals Inc And Encourages Impacted Investors To JoinAccesswire
SPRY
Earnings
- 11/9/23 - Beat
SPRY
Sec Filings
- 6/28/24 - Form 8-K
- 6/28/24 - Form 8-K
- 6/24/24 - Form 4
- SPRY's page on the SEC website